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The increasing adoption of electronic health records (EHRs)1 
and the availability of other data sources, such as administra-
tive claims data2 and spontaneous adverse drug event report-
ing systems,3 promise a new era of medical discovery.4 One 
area that has shown concrete progress is pharmacovigilance.5 
Adverse drug events represent a huge health and economic 
cost to the nation.6–8 It is simply not possible to detect all pos-
sible drug side effects in the drug-approval process because 
of small sample size, narrow study populations, and limited 
time course. Postmarket surveillance of drug safety—that 
is, pharmacovigilance—promises to detect important side 
effects as soon as possible to minimize the damage.
Before regulatory approval, while a drug is in development, 
randomized clinical trials represent the primary sources of 
safety information. Such experiments are generally regarded 
as the highest level of evidence, leading to an unbiased esti-
mate of the average treatment effect.9 Unfortunately, most tri-
als suffer from insufficient sample size and lack of applicability 
to reliably estimate the risk of other potential safety concerns 
for the target population.10,11 As a result, new evidence about 
safety is required even after a medical product is approved.
A number of techniques have been developed to infer drug 
side effects from large databases in the postapproval setting.12 
Spontaneous adverse event reporting databases comprise 
voluntary reports of a suspected relationship between adverse 
effects following medical product exposure. As a result, these 
spontaneous databases present challenges in analysis, 
because there is no defined population from which to base 
the denominator when estimating reporting rates. The reports 
reflect a nonrandom sample from the total patients exposed 
and the total patients who have experienced the adverse 
event, but neither totals are reliably obtained. Disproportion-
ality analysis methods for spontaneous adverse event report-
ing data were established as an approach to account for the 
lack of denominator by using the universe of all reports as a 
proxy to estimate the expected number of events that could be 
compared with the true observed count. Longitudinal obser-
vational health-care databases, such as administrative claims 
and EHRs, offer opportunity to define a population over time, 
enabling the estimation of background rates of events and 
drug utilization patterns, which can then be used as denomi-
nators for evaluating the strength of association between 
exposure and outcomes. However, retrospective observational 
database analyses suffer from a multitude of potential sources 
of bias due to the data capture process and heath-care deliv-
ery system. For example, it is common that the indication for 
a drug may bias the estimated association if it is associated 
with an increased risk of the outcome itself.13 Propensity score 
adjustment,14 self-controlled designs,12 and domain knowledge 
(e.g., indications)15 are commonly used to reduce confound-
ing; however, health records have unreliable timing, and indi-
cations may be correlated so that a second indication may be 
confused with a side effect. Pharmacovigilance also presents 
the challenge of multiplicity, as there are >1,500 active ingredi-
ents in prescription medications and each requires monitoring 
for thousands of potential side effects; however, simultaneous 
evaluation of millions of statistical tests is likely to produce 
many false-positive findings due to chance alone. A number of 
techniques for addressing multiplicity, including false discovery 
rate analysis,16 have been suggested.
The consequence of dependencies, confounding, and other 
“noise” is an unacceptably high false-positive rate. The state 
of the art for pharmacovigilance on the Observational Medi-
cal Outcomes Partnership (OMOP)17 databases, which cover 
140 million lives, produces areas under the receiver operating 
characteristic curve of almost 0.8.18 Even with a high threshold 
(relative risk > 2), which led to an average sensitivity of 0.28, 
the average specificity was only 0.87 and the average positive-
predictive values reached only 0.51. Therefore, the discovery 
of an adverse event association through mining even very 
large databases cannot be used to directly infer actual risks. 
At best, the method generates a smaller pool of hypotheses 
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that warrant further study. The volume of hypotheses when 
applied to all potential outcomes across the entire formulary 
of drugs, however, is likely to be in the hundreds or thousands.
High-visibility drug market withdrawals, such as that of 
rofecoxib,19 have led investigators to assess when its side 
effects could have been discovered according to various 
databases.20–22 Retrospective assessments of the early 
appearance of a signal are common in the literature but are 
misleading as the investigation focuses on a single “known” 
signal rather than establishing the context of looking for these 
signals across an entire set of exposures and outcomes: these 
studies fail to account for the potential false-positive rate that 
would occur if the same method were similarly applied to all 
other drugs for the same outcome. Schuemie et al. have shown 
substantial risk of both false-positives and false-negative 
results when establishing decision thresholds near the effect 
size where rofecoxib signaled.23 Removing all drugs from the 
market whose relative risk confidence interval exceeds one or 
some other threshold is likely to cause more harm than good.
At this point in time, the only possible approach is to manu-
ally review and prioritize generated lists of hypotheses. Experts’ 
domain knowledge of pharmacology, physiology, and health care 
may help in addressing issues such as confounding between 
indications and side effects. In the past, we have used bar plots12 
and forest plots23 to better visualize and interpret pharmaco-
vigilance results, but those approaches fall short because they 
convey no domain knowledge (indication and structure).
Genome-wide association studies identify relevant genetic 
changes associated with disease states from among the thou-
sands to millions of potential sites. The typical visualization of 
these associations shows the statistical significance (–log P 
value) of the target sites compared with all others, where the 
sites are organized by their placement in the genome (see 
for example, Ikram et al.).24 The organization places sites 
within genes near each other and places sites that are geneti-
cally linked near each other. The visualization approach was 
adopted for clinical associations in the so-called phenome-
wide association studies.25 These are an inverse of a genome-
wide study, in which a single genetic locus is compared with 
all possible phenotypes. It is organized by clinical system, 
often using the International Classification of Diseases, 9th 
Revision, Clinical Modification26 for organizing the pheno-
types so that those affecting similar systems are colocated.
Using an approach based on genome- and phenome-wide 
association studies, we propose a “medication-wide associa-
tion study” (MWAS), in which each side effect is compared 
with all drugs available for comparison. We organize the drugs 
by the Anatomical Therapeutic Chemical Classification Sys-
tem,27 which groups drugs both by the organ system on which 
they act and by their therapeutic characteristics and chemical 
structure. We applied a self-controlled case series (SCCS) 
analysis to 6 years’ data from two observational health-care 
databases—the Truven MarketScan Commercial Claims and 
Encounters (CCAE) administrative claims database with 46.5 
million lives, and the GE Centricity EHR database with 11.2 
million lives18—and four clinically important side effects: acute 
myocardial infarction, acute liver failure, acute renal failure, 
and upper gastrointestinal ulcer. We plotted drugs for which 
we had ground truth of either known side effects or known lack 
of side effects according to appropriately powered studies.
reSUltS
Figure 1 shows the four side-effect plots for the Truven Mar-
ketScan CCAE database. For myocardial infarction, a number 
of true associations (star markers) are above the threshold of 
P < 0.05, but there appears to be a class-specific tendency to 
display (e.g., anti-inflammatory) or not display (e.g., psychoa-
naleptics) an effect. Negative controls (circle markers) show 
P values almost as extreme as the true associations. For 
acute liver failure, the results are similar, with some classes 
with known effects displaying it and others not, and with a 
false-positive as high as the highest true-positives. Acute 
renal failure is similar. Upper gastrointestinal ulcer performs 
better with few notable false-positives.
Figure 2 displays the P-value plots across the negative 
controls for each of the four outcomes. In all the cases, the 
proportion of tests with P < 0.05 is substantially higher than 
the 5% expected, indicating that these observational analy-
ses do not satisfy the standard assumptions of independent 
and unbiased estimators.
Figure 3 compares the results for CCAE and the GE Cen-
tricity database. For each drug, a line connects the results for 
the two databases, with the larger marker representing the 
CCAE database. In general, the CCAE P values are lower in 
value and therefore higher on the MWAS plots, likely because 
the database has a larger sample size and more complete 
data capture of health service utilization. The combination of 
the two databases does not appear, however, to help distin-
guish between positive and negative controls.
DiScUSSiOn
Observational health-care databases are commonly used 
for evaluating specific hypotheses about potential drug 
safety issues, but only recently has the research community 
sought to systematically explore these data to proactively 
identify safety signals. In 2007, the US Congress passed 
the Food and Drug Administration Amendment Act, which 
required the Food and Drug Administration to establish a 
“postmarket risk identification and analysis system” with 
access to >100 million lives of electronic health-care data.28 
In response, the Food and Drug Administration established 
the Sentinel Initiative, which has made progress toward 
developing a national data infrastructure, but has not yet 
conducted medication-wide analyses to identify potential 
safety concerns.29 Our work illustrates a proof-of-concept 
approach for signal generation that can enable standardized 
surveillance of specific health outcomes of interest across 
all medical products.
Our MWAS visualizations demonstrate both the oppor-
tunity and challenge of pharmacovigilance in these large 
health-care databases. Most of the signals identified in these 
analyses were positive controls that we would hope a system 
would detect, and the majority of negative controls failed to 
yield statistically significant false-positive associations. This 
performance reflects the previously documented predictive 
value of up to 0.8.18
Nevertheless, for each outcome, we observed a large 
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significant statistical associations. Conversely, many drugs 
known to have effects do not signal despite the large size 
of the database. All the four plots in Figure 1 contain false-
positives (circles) above the Bonferroni-corrected threshold 
of ~0.0005, and three of the four have false-positives at the 
most significant P values. Therefore, the false-positives are 
not due to testing multiple hypotheses and we must consider 
sources of error such as confounding. For example, the very 
strong signal for hydrochlorothiazide causing acute renal 
failure may be due to its common coprescription in patients 
with renal impairment. The self-controlled design used in 
this analysis is only one of several alternative approaches 
that can be considered. While the SCCS explicitly addresses 
time-invariant confounding factors, such as gender, race, and 
genetics, it does not control for time-varying factors other 
than concomitant medication exposure. Other study design 
approaches include a new user cohort design, which uses 
an active comparator as a referent and estimates event rates 
during the time following initiation of treatment, and the case–
control design, which compares exposure rates during the 
time before outcome incidence and compares with exposure 
rates among matched patients who did not experience the 
outcome. We present the results from the SCCS because 
this design has been demonstrated in OMOP’s experiments 
to have higher predictive accuracy and lower bias than these 
alternative approaches.18 Future work should be considered 
to determine how best to combine results across multiple 
analyses to improve our understanding of the effects of medi-
cal products.
If we group drugs by the organ system of their indications 
for each of the four side effects (drugs grouped by color in 
Figure 1), we found a tendency of the drugs to act similarly 
within groups. We found 28 groups where all drugs in the 
organ class were negative and no association was found 
and 5 in which there were drugs with known side effects and 
an association was found in more than half. Thus, 33 of 59 
groups were handled well by the algorithm. In some cases, 
such as the positive effects of nonsteroidal anti-inflammatory 
drugs and acute myocardial infarction, the consistency of the 
findings supports the observation of a potential effect. There 
were 15 groups in which most or all of the known drugs with 
true side effects were missed, 2 groups in which a significant 
proportion of the drugs known not to have a side effect were 
found to have an association, 7 groups with a single spurious 
false-positive association, and 2 groups with a combination 
of a spurious association and incomplete or nearly complete 
identification of true side effects. For example, despite the 
known increased risk of acute liver injury after exposure to 
antivirals, the consistent lack of observed association could 
falsely lead to a conclusion that there is no effect. The ten-
dency of drugs to act similarly within groups probably reflects 
biases due to the health-care process, because in most 
cases, the drugs within a group are not structurally similar. 
Despite the presence of these patterns, no single pattern 
appeared to reliably identify a drug as a true- or false-positive. 
For example, a single association within a group could be 
spurious or true, and a preponderance of associations within 
a group could represent accurate identification, a run of false-
positives, or a combination.
Three of the graphs are notable for a lack of obvious con-
founding by indication. Drugs with an indication that was 
related to the side effects—cardiovascular for myocardial 
infarction, urologic for renal failure, and alimentary track for 
ulcer—did not produce false-positive associations, so the self-
controlled study appeared to work in these cases. For acute 
liver failure, however, the false-positive findings observed for 
alimentary track drugs may be due in some way to the effects 
or treatment of liver failure.
One potential approach to addressing imperfect data is to 
combine evidence from disparate sources. Figure 3 shows 
two very different databases, derived from claims data and 
EHR data. Combining the two does not appear to help dis-
criminate true signals from false ones; similar results were 
found for the other three side effects. We performed addi-
tional experiments with two additional databases and found 
that multiple approaches to synthesize evidence across data-
bases failed to improve discrimination. These results sug-
gest that different health-care databases may exhibit similar 
biases, such that pharmacovigilance activities may require 
information sources beyond observational data to support the 
evaluation of safety signals.
A P-value plot can be a useful test when each test can be 
considered as independent and unbiased.30 You can deter-
mine whether the number of significance tests is consistent 
with the unbiased, independence assumption by assessing 
whether the range of tests does not deviate from the 45% line. 
In the context of observational studies, we expect that results 
may be biased, and studies of the same outcome are likely 
correlated insofar as the sources of bias for a given outcome 
may be consistent across multiple drugs. This can be seen 
from the P-value plots of the negative controls  (Figure 2), 
which show a disproportionate number of significant findings. 
For this reason, we argue that statistical significance using tra-
ditional P values or multiplicity-adjusted thresholds are insuf-
ficient, and instead rank-ordering effects based on P value, 
as we display in the MWAS plots, may be a more principled 
approach to triaging potential drug safety concerns.
The MWAS approach of systematic exploration of struc-
tured observational health-care claims and EHR databases is 
only one tool to complement other recent innovations toward 
improving the evidence base about the safety profile of medi-
cal products. LePendu et al. have demonstrated how natural 
language processing of free text in medical records can be 
used to draw inferences about potential drug–side effect rela-
tionships.31 Harpaz et al. recently measured the performance 
of new algorithms for data mining in spontaneous adverse 
event reporting data and demonstrated that disparate data 
may have differential performance across health outcomes 
of interest.32 Tatonetti et al.33,34 and Duke et al.35 have suc-
cessfully demonstrated the potential to go beyond studying 
Figure 1 Medication-wide association study (MWAS) analyses in Commercial Claims and Encounters (CCAE) database for (a) acute 
myocardial infarction, (b) acute liver injury, (c) acute kidney injury, and (d) upper gastrointestinal bleeding. Y-axis displays P values on the 
negative log scale. X-axis displays all the drugs studied for a given outcome, grouped by the Anatomical Therapeutic Chemical classification 
system. OMOP, Observational Medical Outcomes Partnership.











































































































































































































the main effects to also explore drug–drug interactions in the 
same data, and to integrate the results of observational anal-
ysis with other information sources, such as the published lit-
erature and chemical structure ontologies.
MWASs provide a structured approach for evaluating 
potential drug safety concerns across all products in a way 
that provides the necessary context for interpreting any one 
drug-safety question of interest. While these illustrations 
focus on a defined set of negative and positive control test 
cases for methodological purposes, we believe this graphical 
representation provides a consistent framework that can be 
applied to all drugs and outcomes as a means to assess the 
drug–outcome pairs for which we are still uncertain about the 
true extent of the potential relationship. That context involves 
understanding how unique a particular observation is by see-
ing how many other drugs yielded similar effects, and also 
involves seeing how consistent findings are with medical 
products that share similar characteristics. Further context 
is provided by evaluating an association through replication 
within two or more data sources. In this regard, the MWAS 
visualization using an SCCS analysis across multiple data-
bases provides a framework that embodies several of the 
elements required for evaluating a potential causal effect, 
including strength of association, consistency, temporality, 
specificity, and coherence.36 Observational health-care data 
alone may not be sufficient to provide definitive evidence of 
any purported effect; however, systematic analysis of these 
data offers tremendous potential in providing credible evi-
dence for advancing our understanding of the effects of medi-
cal products across large populations and a wide variety of 
products.
MetHODS
We conducted this analysis in two observational health-care 
databases, the Truven MarketScan CCAE administrative 
claims database and the GE Centricity EHR database.18 
CCAE represents a privately insured population and captures 
inpatient and outpatient medical claims and pharmacy claims 
of multiple insurance plans. The database used in this analy-
sis contained 46.5 million lives with >97.6 million patient-
years of observation from 2003 to 2009. We defined periods 
of drug exposure based on pharmacy dispensing records and 
procedural administrations. The GE MQIC (Medical Quality 
Improvement Consortium) represents the group of provid-
ers who use the GE Centricity Electronic Medical Record 
and who contribute their data for secondary analytic use. 
The GE MQIC database reflects events in usual care, includ-
ing patient problem lists, prescribing patterns and over-the-
counter use of medications, and other clinical observations as 
experienced in the ambulatory care setting. GE contains 11.2 
million lives with data from 1996 to 2008. Drug exposures 
were inferred from medication history and prescriptions writ-
ten. For both databases, we applied standardized algorithms 
to define acute myocardial infarction, acute liver failure, acute 
renal failure, and upper gastrointestinal bleeding based on 
diagnosis codes on patient and outpatient medical claims.37
For each outcome, we identified a set of negative and 
positive controls. Ground truth was established based on sys-
tematic literature review and natural language processing of 
structured product labeling, with positive controls identified as 
drugs with Boxed Warnings or Precautions that are supported 
by published evidence with no conflicting published studies, 
and negative controls defined as drugs with no evidence sug-
gesting an association in either labeling or literature.38 Drugs 
with inconsistent evidence were excluded. The MWAS plots 
shown in Figure 1 display the full set of negative and posi-
tive controls for each outcome that were tested as part of the 
OMOP experiment. The specific number of drugs varies by 
outcome; 118 drugs were studied for acute liver injury, 102 
for acute myocardial infarction, 88 for acute renal failure, and 
91 for gastrointestinal bleeding. Analyses were performed on 
RxNorm ingredient concepts. RxNorm concepts were clas-
sified using the Anatomical Therapeutic Chemical hierarchy 
only for presentation purposes, but this classification does 
not affect the effect estimation procedure. The RxNorm-to-
Anatomical Therapeutic Chemical mapping is part of the 
OMOP vocabulary model and was created by and licensed 
from FirstDataBank. The entire OMOP vocabulary is publicly 
available online (http://omop.org/CDMvocabV4).
For each drug–outcome pair, we performed an SCCS 
analysis,39,40 which compares the event rate during time-at-
risk with the rate during the time unexposed among patients 
who had at least one exposure and one outcome record. We 
defined time-at-risk as the all-time postexposure start, includ-
ing the index date when treatment was initiated and continuing 
through the end of the patient’s observation period. All time 
before starting the drug exposure is considered as the unex-
posed period. We included all occurrences of outcome. We 
applied a regularized implementation of the SCCS model,41 
with the regularization parameter determined by crossvalida-
tion, and we did multivariate adjustment for time-varying con-
comitant medications. The multivariate SCCS implementation 
uses all RxNorm ingredients as potential covariates in the 
model. Only those RxNorm ingredients which are observed 
in patients with exposure to the target drug and an occur-
rence of the event are actually fit within each model. Each 
analysis produced an incidence rate ratio, 95% confidence 
interval, and P value. The MWAS plot displays the P value on 
the negative log scale across all drugs for the same outcome. 
Drugs are grouped according to the Anatomical Therapeu-
tic Chemical classification system. The source code of the 
SCCS implementation used to produce this analysis is pub-
licly available online (http://omop.org/MethodsLibrary). The 
entire result set of all methods executions across a network 
of observational databases for all drug-outcome test cases is 
also publicly available online (http://omop.org/Research).
Only fully deidentified data sets were used in the study and 
only aggregate-level data are reported, so the review by Insti-
tutional Review Board was not required.
Figure 2 P-value plots for negative controls, trellised by outcome. Y-axis lists the P value for each drug–outcome pair and X-axis shows the 
percentile of the negative control drugs which have a P value at or below that P value. The black dashed line indicates the 45° line, which should 
approximate the P-value curves if the statistical tests were independent and unbiased. CCAE, Commercial Claims and Encounters; OMOP, 
Observational Medical Outcomes Partnership.
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